Support in USA : 1-978- 707-9553 / Support in India : +91- 9987711567

  • Apple Pharmaceuticals

Myhep Lvir - 12 weeks

HepatitisC-Mylan-Ledipasvir-90mg-Sofosbuvir-400mg-Myhep-LVIR

Availability: In stock

Special Price $ 749

BRAND : Myhep Lvir
STRENGTH : 400mg & 90mg
INGREDIENT : HepatitisC-Mylan-Ledipasvir-90mg-Sofosbuvir-400mg-Myhep-LVIR
COMPANY NAME : Mylan
COUNT : 28 Tablets



Description of Myhep Lvir - 12 weeks

Myhep LVIR containing active components like sofosbuvir and ledipasvir, these dose combinations used in the treatment of chronic hepatitis C virus in adults and children who are at least 12 years or 77 pounds

Myhep LVIR tablets are accomplished in the therapy of hepatitis C viral infection. The continuation of treatment of Myhep LVIR tablets occurs in 12 weeks.

 Myhep LVIR tablet commonly used as single dose therapy; which may used alone or in chronic conditions it may concomitant with ribavirin

Myhep LVIR product identification 12 weeks

  • Trade name: Myhep LVIR
  • Active components: Sofosbuvir & Ledipasvir
  • Strength availability: 400mg & 90mg respectively
  • Mfg: Mylan pharmaceuticals
  • Package: 28 tablets in a container
  • Classification: Anti-hepaciviral drugs

Pharmacology of Myhep Lvir - 12 weeks

Mechanism of action:

Ledipasvir: It is a NS5A, which is a protein essential for viral multiplication and association of HCV virions. Ledipasvir interfere with NS5A protein activity and terminates the viral replication

Sofosbuvir:

It is a nucleotide inhibitor; especially prohibits HCV NS5B RNA polymerase, Sofosbuvir is metabolized into active form which is known as triphosphate uridine analogue. Sofosbuvir is inserted into viral RNA by NS5B polymerase and performed as chain terminator. Sofosbuvir is interfere in viral replication process

Myhep LVIR pharmacokinetics for 12 weeks

Absorption:

After oral administration, sofosbuvir was absorbed very fastly

The peak median plasma concentration of; Ledipasvir peak plasma concentration occurs in 4 to 4.5 hours after drug intake; Sofosbuvir was observed in-between 0.8 to 1 hour; Circulating metabolite GS-331007, its peak plasma concentration occurs between 3.5 to 4 hours after oral administration

Effect of food:

The response rate of Myhep LVIR tablets did not alter by food, so it may administer with or without food in HCV infected patients

Distribution:

The human plasma protein bound of ledipasvir nearly >99.8%; sofosbuvir occurs nearly 61 to 65% and the circulating metabolite GS-331007 was minimal

Metabolism:

Myhep LVIR tablets are metabolized in liver; whereas sofosbuvir metabolized into active pharmacological form like triphosphate uridine analogue. The metabolic pathway occurred by hydrolysis with the help of catalyst cathepsin A which is followed by phosphorylation

The Dephosphorylation leads to form circulating metabolite called GS-331007 which has poor Anti-HCV activity

Elimination:

Sofosbuvir excreted as 80%, 14% & 2.5% through urine, feces & exhaled air respectively

Ledipasvir excreted in feces and urine; almost 70% of unchanged form of ledipasvir eliminated through feces.

The terminal half life period of sofosbuvir ledipasvir and metabolite GS-331007 are 0.5, 47 & 27 hours

Indication of Myhep Lvir - 12 weeks

Dose & Dosage's of Myhep Lvir - 12 weeks

Myhep LVIR tablets containing 90mg of ledipasvir and 400mg of sofosbuvir

The usual prescribed dosage of Myhep LVIR tablets are;

Genotype I

Therapy naïve with or without cirrhosis:

The usual Myhep LVIR dose is one tablet to be taken for 12 weeks as a single dose

It should be administered with or without food

Therapy experienced without cirrhosis:

The usual Myhep LVIR dose is one tablet to be taken for 12 weeks as a single dose

It should be administered with or without food

Therapy experienced with cirrhosis:

The usual Myhep LVIR dose is one tablet to be taken for 24 weeks as a single dose

It should be administered with or without food

Therapy experienced with decompensated cirrhosis:

Myhep LVIR tablet should be combined with ribavirin for 12 weeks

Genotype I or IV:

Treatment naïve or experienced liver transplant recipients without cirrhosis or compensated cirrhosis:

One Myhep LVIR tablet should be combined with ribavirin for 12 weeks

Genotype IV, V or VI:

In liver transplant recipients without cirrhosis or compensated cirrhosis:

One Myhep LVIR tablet should be taken as single dose for 12 weeks

In pediatric:

Genotype I:

Treatment naïve without cirrhosis or with compensated cirrhosis:

One Myhep LVIR tablet should be taken as a single dose for 12 weeks

Treatment experienced patients without cirrhosis:

One Myhep LVIR tablets should be taken as a single dose for 12 weeks

Compensated cirrhosis:

One Myhep LVIR tablet should be taken as single dose for 24 weeks

Genotype IV, V or VI:

Without cirrhosis or with compensated cirrhosis: one Myhep LVIR tablet to be taken as a single dose for 12 weeks.

Missed dose:

If patients fail to take the dose of tablet Myhep LVIR, must consult the physician and take the medicine as soon as possible otherwise the missed dose should be skipped and follow the regular dosing schedule

Myhep LVIR tablet is a prescription medicine; it is used only by the guidance of medical practitioner

Side Effects of Myhep Lvir - 12 weeks

  • Unusual tiredness
  • Cough
  • Loss of strength
  • Trouble breathing
  • Chest pain or discomfort       
  • Headache
  • Diarrhea
  • Irritability
  • Increased bilirubin
  • Hepatitis B reactivation
  • Myalgia
  • Elevated creatine kinase
  • Muscle pain
  • Nausea
  • Trouble sleeping
  • Loss of appetite
  • Anemia
  • Increased lipase
  • Dizziness or fainting
  • Irregular heartbeat

Contraindication of Myhep Lvir - 12 weeks

Myhep LVIR combined with ribavirin, causes fetal death. It may contraindicated to pregnancy women

Patients may have chance to get hypersensitivity reaction while taking Myhep LVIR tablet. Hypersensitivity reaction occurred due to component present in the Myhep LVIR

Drug Interaction of Myhep Lvir - 12 weeks

Co administration of Myhep LVIR with digoxin causes increase in concentration of digoxin

Myhep LVIR with anti-convulsants: reduce the effect of concentration of Myhep LVIR tablets

Ledipasvir is drug transporter inhibitors, while co administration of these substrates with Myhep LVIR tablets may causes increased intestinal absorption

Some anti-retroviral agents may causes reduction in effect of concentration of Myhep LVIR while combination

Myhep LVIR tablet with acid reducing agents causes decrease in effect of concentration of ledipasvir

Myhep LVIR tablet with amiodarone causes bradycardia in severe conditions

P-gp inducers (st. Johns wort): concomitant with Myhep LVIR tablets leads to reduce the plasma concentration of Myhep LVIR which causes depletion in therapeutic effect

Myhep LVIR tablet with anti-mycobacterials: may leads to reduce concentration of Myhep LVIR tablet

Precaution of Myhep Lvir - 12 weeks

Risks related with ribavirin combination therapy

Caution with use in renal impairment and hepatic impairment patients

Serious bradycardia occurs while concomitant with amiodarone

Concurrent use of PgP inducers and Myhep LVIR tablet causes depletion in therapeutic effect

Usage & Safety profile of Myhep Lvir - 12 weeks Pregnancy & Lactation

Myhep LVIR tablets are comes under a pregnancy category: B1

Myhep LVIR while combining with ribavirin comes under pregnancy category: X

Myhep LVIR as monotherapy in 12 weeks therapy i.e.; it used alone means it is safe in pregnancy, if it is combined with ribavirin causes fetal harm even to death

Breast feeding is not recommended for 12 weeks therapy

Storage of Myhep Lvir - 12 weeks

Myhep LVIR container should be stored at room temperature not exceeding 30oC

Myhep LVIR Container must be keep away from moisture, heat and light.